DUBLIN--(BUSINESS WIRE)--The "Biosurgery Market by Product (Fibrin/Collagen Sealant, Hemostats, Adhesion Barriers, Biological Meshs, Soft Tissue Attachments, Stapler, Bone Graft Substitutes) Application (Orthopedic, Gynecology, Cardiovascular, Reconstructive) - Forecast to 2023" report has been added to ResearchAndMarkets.com's offering.
The biosurgery market is projected to reach USD 15.58 billion by 2023 from estimated USD 11.36 billion in 2018 at a CAGR of 6.5%
Factors such as the growing geriatric population and corresponding chronic diseases, increasing volume of surgeries and prevalence of severe trauma injuries, and rising need for effective blood loss management in patients are expected to drive the growth of this market during the forecast period of 2018 to 2023. However, stringent regulatory framework and the requirement of skilled personnel for the effective use of biosurgery products may challenge market growth to a certain extent in the coming years.
On the basis of product, the biosurgery is broadly segmented into bone-graft substitutes, soft-tissue attachments, hemostatic agents, surgical sealants and adhesives, adhesion barriers, and staple-line reinforcement agents. The surgical sealants and adhesives segment is expected to register the highest CAGR during the forecast period. The growth of this segment can be attributed to a large number of commercially available sealants and their higher utilization (as compared to other biosurgery products) by surgeons in various surgeries.
Key Topics Covered:
1 Biosurgery Market: Introduction
2 Biosurgery Market: Research Methodology
3 Biosurgery Market: Executive Summary
4 Biosurgery Market: Premium Insights
5 Biosurgery Market: Overview
6 Industry Insights
7 Biosurgery Market, By Product
8 Biosurgery Market, By Application
9 Biosurgery Market, By Region
10 Biosurgery Market: Competitive Landscape
11 Company Profiles
- Baxter International, Inc.
- B.Braun Melsungen AG
- C.R. Bard
- Johnson & Johnson
- Medtronic, PLC.
- MAQUET Holding B.V. & Co. Kg. (Getinge Group)
- Cohera Medical Inc.
- Integra Lifesciences Holdings Corporation
- Commonwealth Serum Laboratories (CSL)
- Hemostasis, LLC
- Pfizer Inc.
- Stryker Corporation
- Cryolife, Inc.
For more information about this report visit https://www.researchandmarkets.com/research/7vh6d6/global_biosurgery?w=4